Ignite Creation Date:
2024-05-05 @ 9:03 PM
Last Modification Date:
2024-10-26 @ 9:58 AM
Study NCT ID:
NCT00805753
Status:
COMPLETED
Last Update Posted:
2014-10-13
First Post:
2008-12-09
Brief Title:
Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
A Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy MN
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MN
Brief Summary:
This pilot study is aimed at demonstrating the effectiveness of ACTH HP Acthar Gel on the lipid profile and proteinuria in participants with MN ACTH or adrenocorticotrophin is a hormone produced by the pituitary gland a gland at the base of your brain that is involved in stimulating your adrenal glands to secrete a number of steroid products eg cortisol aldosterone corticosterone and others that are important in keeping you alive The drug used in this study has been approved by the Food and Drug Administration FDA for routine clinical use in the treatment of patients with proteinuria and patients with idiopathic nephrotic syndrome such as idiopathic MN However the most adequate dose to use has not been adequately assessed This is the reason for conducting this research study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None